These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 22296082)

  • 1. Uterine fibroids and evidence-based medicine--not an oxymoron.
    Stewart EA
    N Engl J Med; 2012 Feb; 366(5):471-3. PubMed ID: 22296082
    [No Abstract]   [Full Text] [Related]  

  • 2. Selective progesterone receptor modulators (SPRMs) for uterine fibroids.
    Murji A; Whitaker L; Chow TL; Sobel ML
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD010770. PubMed ID: 28444736
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guideline No. 389-Medical Management of Symptomatic Uterine Leiomyomas - An Addendum.
    Laberge PY; Murji A; Vilos GA; Allaire C; Leyland N; Singh SS
    J Obstet Gynaecol Can; 2019 Oct; 41(10):1521-1524. PubMed ID: 31548041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ulipristal acetate versus leuprolide acetate for uterine fibroids.
    Donnez J; Tomaszewski J; Vázquez F; Bouchard P; Lemieszczuk B; Baró F; Nouri K; Selvaggi L; Sodowski K; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):421-32. PubMed ID: 22296076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ulipristal acetate compared with leuprorelin acetate for Japanese women with symptomatic uterine fibroids: a phase III randomized controlled trial.
    Osuga Y; Nakano Y; Yamauchi Y; Takanashi M
    Fertil Steril; 2021 Jul; 116(1):189-197. PubMed ID: 33715871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Translational research in women's health: from bedside to bench and from bench to bedside.
    Maruo T
    Int J Gynaecol Obstet; 2010 May; 109(2):83-4. PubMed ID: 20172522
    [No Abstract]   [Full Text] [Related]  

  • 7. Ulipristal acetate for uterine fibroid-related symptoms.
    Puchar A; Luton D; Koskas M
    Drugs Today (Barc); 2015 Nov; 51(11):661-7. PubMed ID: 26744741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ulipristal acetate for the management of large uterine fibroids associated with heavy bleeding: a review.
    Donnez J; Courtoy GE; Donnez O; Dolmans MM
    Reprod Biomed Online; 2018 Aug; 37(2):216-223. PubMed ID: 29706284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ulipristal acetate versus placebo for fibroid treatment before surgery.
    Donnez J; Tatarchuk TF; Bouchard P; Puscasiu L; Zakharenko NF; Ivanova T; Ugocsai G; Mara M; Jilla MP; Bestel E; Terrill P; Osterloh I; Loumaye E;
    N Engl J Med; 2012 Feb; 366(5):409-20. PubMed ID: 22296075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ulipristal acetate in the management of symptomatic uterine fibroids: facts and pending issues.
    Pérez-López FR
    Climacteric; 2015 Apr; 18(2):177-81. PubMed ID: 25390187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic review and meta-analysis of ulipristal acetate for symptomatic uterine fibroids.
    Ghonim M; Magdy R; Sabbour M; Ghonim M; Nabhan A
    Int J Gynaecol Obstet; 2019 Aug; 146(2):141-148. PubMed ID: 31127621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The past, present, and future of selective progesterone receptor modulators in the management of uterine fibroids.
    Singh SS; Belland L; Leyland N; von Riedemann S; Murji A
    Am J Obstet Gynecol; 2018 Jun; 218(6):563-572.e1. PubMed ID: 29274830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ulipristal acetate for use in moderate to severe symptoms of uterine fibroids.
    Talaulikar VS; Manyonda I
    Womens Health (Lond); 2014 Nov; 10(6):565-70. PubMed ID: 25482483
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective progesterone receptor modulators.
    Whitaker LH; Williams AR; Critchley HO
    Curr Opin Obstet Gynecol; 2014 Aug; 26(4):237-42. PubMed ID: 24950125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in proliferating and apoptotic markers of leiomyoma following treatment with a selective progesterone receptor modulator or gonadotropin-releasing hormone agonist.
    Yun BS; Seong SJ; Cha DH; Kim JY; Kim ML; Shim JY; Park JE
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():62-7. PubMed ID: 26093349
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Esmya
    Powell M; Dutta D
    Womens Health (Lond); 2016 Nov; 12(6):544-548. PubMed ID: 29334010
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Selective progesterone receptor modulator (ulipristal acetate--a new option in the pharmacological treatment of uterine fibroids in women].
    Szamatowicz M; Kotarski J
    Ginekol Pol; 2013 Mar; 84(3):219-22. PubMed ID: 23700851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progestin-releasing intrauterine systems and leiomyoma.
    Kaunitz AM
    Contraception; 2007 Jun; 75(6 Suppl):S130-3. PubMed ID: 17531604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Individualized vaginal bleeding experience of women with uterine fibroids in the PEARL I randomized controlled trial comparing the effects of ulipristal acetate or placebo.
    Barlow DH; Lumsden MA; Fauser BC; Terrill P; Bestel E
    Hum Reprod; 2014 Mar; 29(3):480-9. PubMed ID: 24457604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Ulipristal acetate and SPRM: A new entity for the therapeutic strategy for symptomatic myomas].
    Fernandez H
    Gynecol Obstet Fertil Senol; 2018 Nov; 46(10-11):671-672. PubMed ID: 30293948
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.